Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

[Evaluation of preserved insulin secretion in children and adolescents with type 1 diabetes].

Wegner O, Wyka K, Fendler W, Zmysłowska A, Młynarski W.

Pediatr Endocrinol Diabetes Metab. 2010;16(2):67-71. Polish.

PMID:
20813081
2.
3.

C-peptide: an index of insulin secretion.

Faber OK, Binder C.

Diabetes Metab Rev. 1986;2(3-4):331-45. Review.

PMID:
3527619
4.

[C-peptide residual secretion makes difference on type 1 diabetes management?].

Rodacki M, Milech A, Oliveira JE.

Arq Bras Endocrinol Metabol. 2008 Mar;52(2):322-33. Review. Portuguese.

5.

Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.

Eldor R, Kassem S, Raz I.

Diabetes Metab Res Rev. 2009 May;25(4):316-20. doi: 10.1002/dmrr.942. Review.

PMID:
19267355
6.

C-peptide in the natural history of type 1 diabetes.

Palmer JP.

Diabetes Metab Res Rev. 2009 May;25(4):325-8. doi: 10.1002/dmrr.943. Review.

7.

Residual C-peptide in type 1 diabetes: what do we really know?

VanBuecken DE, Greenbaum CJ.

Pediatr Diabetes. 2014 Mar;15(2):84-90. doi: 10.1111/pedi.12135. Review.

PMID:
24645775
8.

The role of immunomodulation therapy in autoimmune diabetes.

Ludvigsson J; Linköping Diabetes Immune Intervention Study Group.

J Diabetes Sci Technol. 2009 Mar 1;3(2):320-30. Review.

9.

Revisiting multiple models of progression of β-cell loss of function in type 1 diabetes: Significance for prevention and cure.

Li X, Cheng J, Zhou Z.

J Diabetes. 2016 Jul;8(4):460-9. doi: 10.1111/1753-0407.12376. Review.

PMID:
26754489
10.

C-peptide antioxidant adaptive pathways in β cells and diabetes.

Luppi P, Drain P.

J Intern Med. 2017 Jan;281(1):7-24. doi: 10.1111/joim.12522. Epub 2016 Jun 2. Review.

PMID:
27251308
11.

The latest pharmacotherapy options for type 1 diabetes.

Ludvigsson J.

Expert Opin Pharmacother. 2014 Jan;15(1):37-49. doi: 10.1517/14656566.2014.855197. Epub 2013 Nov 30. Review.

PMID:
24289822
12.

Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data.

Brown RJ, Rother KI.

Pediatr Diabetes. 2008 Jun;9(3 Pt 2):14-22. doi: 10.1111/j.1399-5448.2007.00272.x. Epub 2008 Jan 24. Review. No abstract available.

13.

Trials in the prevention of type 1 diabetes: current and future.

Wherrett DK.

Can J Diabetes. 2014 Aug;38(4):279-84. doi: 10.1016/j.jcjd.2014.05.004. Review.

14.

Prevention of type 1A diabetes mellitus.

Eisenbarth GS.

Endocr Pract. 2012 Sep-Oct;18(5):745-9. doi: 10.4158/EP12080.OR. Review.

15.

Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase.

Gorus FK, Keymeulen B, Veld PA, Pipeleers DG.

Expert Rev Clin Immunol. 2013 Dec;9(12):1173-83. doi: 10.1586/1744666X.2013.856757. Review.

PMID:
24215407
16.

Metabolic abnormalities in the pathogenesis of type 1 diabetes.

Zheng S, Mathews CE.

Curr Diab Rep. 2014;14(9):519. doi: 10.1007/s11892-014-0519-8. Review.

17.

Therapies to Preserve β-Cell Function in Type 1 Diabetes.

Ludvigsson J.

Drugs. 2016 Feb;76(2):169-85. doi: 10.1007/s40265-015-0511-x. Review.

PMID:
26645223
18.

Immunological pathways to β-cell damage in Type 1 diabetes.

Peakman M.

Diabet Med. 2013 Feb;30(2):147-54. doi: 10.1111/dme.12085. Review.

PMID:
23199020
19.

[C-peptide physiological effects].

Shpakov AO, Granstrem OK.

Ross Fiziol Zh Im I M Sechenova. 2013 Feb;99(2):196-211. Review. Russian.

PMID:
23650733

Supplemental Content

Support Center